Marinus Pharmaceuticals’ Phase 3 RAISE Trial of IV Ganaxolone Shows Promising Results for Refractory Status Epilepticus’
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), renowned for its pioneering work in the realm of seizure disorder treatments, has announced encouraging topline results from its Phase 3 RAISE trial (NCT04391569). The study assessed the safety and efficacy of intravenous (IV) ganaxolone in patients suffering from refractory status epilepticus (RSE). This critical condition, marked by prolonged continuous or rapidly recurring seizures, often remains unresponsive to first-line treatments, posing severe health risks and complications.
RSE is a neurologic emergency that demands prompt and effective intervention. Standard treatment protocols typically involve the administration of benzodiazepines followed by second-line antiepileptic drugs (AEDs). However, approximately 30% of patients fail to respond to these measures, necessitating alternative therapeutic strategies like IV anesthetic agents, which come with a host of potential adverse effects and require intensive monitoring.
The RAISE trial was a double-blind, randomized, placebo-controlled study, meticulously designed to evaluate ganaxolone’s potential in this challenging clinical scenario. The primary endpoint was the proportion of patients achieving seizure cessation for a continuous period of 24 hours within 48 hours of treatment initiation, without needing additional rescue medications.
According to Marinus Pharmaceuticals, the RAISE trial’s results are promising. Patients treated with IV ganaxolone exhibited a statistically significant higher rate of seizure cessation compared to the placebo group. Moreover, the safety profile of ganaxolone was consistent with earlier studies, indicating it was well-tolerated with no unexpected adverse reactions.
Dr. Scott Braunstein, CEO of Marinus Pharmaceuticals, expressed optimism regarding the trial outcomes. These results represent a significant advancement in our quest to offer a new therapeutic option for patients with refractory status epilepticus, a condition with limited effective treatments and poor prognoses. We are eager to proceed with our discussions with regulatory authorities and prepare for a potential submission for marketing approval.
The company intends to submit detailed data from the RAISE trial for upcoming medical conferences and peer-reviewed publications, further delineating the clinical implications of their findings. If approved, IV ganaxolone could become a pivotal addition to the therapeutic arsenal for RSE, potentially transforming patient outcomes and mitigating the burdens associated with current treatment methodologies.
Overall, the RAISE trial not only underscores Marinus Pharmaceuticals’ commitment to addressing unmet medical needs in neurology but also spotlights their innovative approach in developing targeted treatments for complex seizure disorders.
Comments